Life Sciences Archive » March, 2011

Life Sciences - March, 2011

225 articles

• J&J Judgment In Stent Patent Suit Climbs To $593M
• Cephalon Investor Sues Over $5.7B Valeant Bid Rebuff
• FDA Panel Calls For More Study On Food Dyes, ADHD
• Actavis Pays $10M To Exit Kentucky Medicaid Suit
• Judge Lets Yaz Counterclaims Against Bayer Stand
• Swisslog Prevails In McKesson Drug Dispenser IP Suit
• WilmerHale Snatches Howrey, Munger Tolles IP Attys
• Aventis Settles Suit Over Allegra Patent
• Judge Nixes Dismissal Bid In Thalomid Antitrust Suit
• Biolitec Laser Doesn't Infringe AMS Patent: Judge
• Ex-Yelp Sales Worker Launches OT Class Action
• Medtronic Didn't Infringe BSC Defibrillator IP: Judge
• GSK Gets $3.5M Verdict In Norvir Antitrust Case
• FDA Weighs Testimony On Health Risks Of Food Dyes
• CDC Probes Bacteria Outbreak From Contaminated IVs
• DC Resident's FCA Claims Killed In Vioxx Fight
• Sanofi Can't Nix Shareholder Suit Over Zimulti
• Novartis, Elan Sue IPC Over Generic Focalin XR
• Generics Makers Ask High Court For State Law Shield
• Pronova, Apotex Strike Deal Over Generic Lovaza
• Paxil Suits Remanded To State Court, To GSK's Chagrin
• Sullivan & Cromwell Reps Valeant In $5.7B Cephalon Bid
• Lannett Loses Bid To Enforce Celgene Oral Agreement
• Elan, Abbott Settle With Lupin Over Generic TriCor
• J&J Recalls Tylenol Products Amid Odor Concerns
• SEC Says FDA Chemist Made $3.6M In Insider Trading
• Fed. Circ. Fines Sun, Caraco Attys In Eloxatin IP Case
• Pfizer Subsidiary Recalls Mislabeled Drugs
• Apotex Must Return $28M Award To Servier: UK Court
• Judge Rules Generic Drug Infringes Dermalogix Patent
• Chattem To License LecTec Patch Patents For $3.6M
• FTC OKs $76M Astellas-Maxygen Protein Program Deal
• High Court Kills County's Drug Price Class Action
• Cephalon Loses Bid For Quick Win In Marketing Suit
• Merck To Pay $4.2M To End Wis. Medicaid Fight
• Pfizer Beats False Marking Claims
• High Court Seeks US' View In Prandin Use Code Case
• Drugstore.com Investor Fights $409M Walgreen Deal
• Fed. Circ. Revives Watson Challenge Of Seasonique IP
• CORRECTED: FTC OKs Quest's $740M Buyout Of Athena
• Class Rep Pushes To Kill Deal Over Chemo Drug Sales
• Purdue Sues Watson Over Generic OxyContin
• Medtronic Unit Must Face Antitrust Claims: Judge
• Animal Health Investor Contests $251M Lextron Deal
• False Marking Law Found Constitutional In GSK Case
• US To Take False Marking Law To Fed. Circ.
• Wyeth Takes $58M Loss In Hormone Case To High Court
• Howmedica Asks High Court To Weigh Polymer IP Case
• 2nd Circ. Affirms Suntrust Win In Defamation Suit
• Cephalon Wins IP Suit Over Watson's Generic Fentora
• Haynes & Boone Adds Ex-Howrey Antitrust Atty
• Par Sues UCB Over Generic Keppra
• Drug Sales Rep Sues Eisai Over OT Pay
• An Adverse Event For Statistical Significance
• $8.9M Nuvelo Class Action Deal Wins Preliminary OK
• ITC Takes Up 337 Probe Of Merck's NuvaRing
• Point Blank CEO Hit With Lawsuit Over SEC Deal
• Medtronic Unit Settles Faulty Spinal Implant Suit
• J&J Unit Yanks 360K Surgical Drain Products
• Solvay Wants Firms, Expert Removed In AndroGel Suit
• Fed. Circ. Nixes Apotex Appeal In Taxotere IP Fight
• Abbott Strikes Deal In Antitrust Battle Over HIV Drugs
• Medtronic, NuVasive Spinal Surgery IP Suit Continues
• 4 Views On Medical Device Preemption
• Jones Day Reps P&G in Joint Venture With Teva
• Sidley, Weil Rep Walgreen In $409M Drugstore.com Buy
• J&J Unit Downplayed Risperdal's Diabetes Link: Jury
• Terumo To Pay $35M Over Heart Device Violations
• Ex-GSK Atty Gets Indictment Over Wellbutrin Tossed
• Abbott, WARF End Zemplar Patent Suit Against Anchen
• FTC Blesses Daiichi Sankyo's $805M Plexxikon Buy
• HIG Picks Up Teleflex's Marine Biz For $122M
• Celera Investor Sues To Block $344M Quest Deal
• Utah University Sues Planck, MIT Over RNA Patents
• Takeda Sues Apotex Over Generic Actos
• Abbott Files New Simcor Patent Suit Against Teva
• Matrixx Opens Door For Plaintiffs, But Only A Crack
• Pfizer Unit To Exit Ch. 11 With $265M Asbestos Deal
• FTC Warns Miss. Lawmakers Over Drug Manager Bill
• Actavis Agrees To Hold Off On Generic Nuvigil
• BSC Can't Shake Contract Claim In Stent Patent Suit
• Sanofi, Merck Drop Animal Health Joint Venture
• Actonel Makers Launch 2nd Suit Over Mylan Generic
• Zuckerman Taps Buc & Beardsley FDA Pros
• Indicted GSK Atty Says Prosecutors Misled Grand Jury
• MetaMorphix Seeks To Convert Case To Ch. 7
• Judge Asked To Toss Troutman Atty's Real Estate Suit
• Angiotech Seeks US Approval Of Canada Restructuring
• Female Bayer Workers Launch $100M Sex Bias Suit
• High Court Won't Hear Mylan IP Fight Over Benicar
• Milbank Technology Head Departs For Dewey
• Camera-Pill Maker Triumphs In Endoscopy Patent Suit
• Morrison Ruling Doesn't Bar Elan ADR Suit: Judge
• 5 Marketing Lessons From Howrey's Graveside
• Duane Reade Escapes $7M Kasowitz Legal Fee Spat
• 1st Circ. Nixes NeuroMetrix Device Securities Suit
• Mylan Pushes FDA To Rule On Ranbaxy's Lipitor ANDA
• Recall: Prevent, Manage, Mitigate And Survive
• Medco Sued Over CalPERS Bribery
• Coudert Settles Bard Unit's $25M Malpractice Claim
• Calif. Joins Relator's Kickback Suit V. Bristol-Myers
• Convicted Trader Protests SEC Penalty In 2nd Circ.
• Judge Backs $2.8M Penalty In Insider Trading Suit
• US Sues Teva Over Generic HIV Drug
• SigmaPharm Appeals Skelaxin Antitrust, Contract Suit
• CDC Proposes New HIV Test Timeline For Organ Donors
• Nycomed Faces IP Suit Over Solaraze Gel
• Mich. Can't Sue Merck Over Vioxx, Appeals Court Says
• Orchid Can't Nix Roche Boniva Patent
• Labeling Gaffe Sparks Mylan Drug Recall In Canada
• FDA Panel Pushes Menthol Cigarette Ban
• Shearman Reps Quest Diagnostics In $344M Celera Buy
• Bayer Birth Control Patents Mostly Survive UK Suit
• FDA Head Takes $4.3B Budget Defense To Senate
• ITC Launches 337 Case Over Lilly's Gemzar Patent
• 1st Circ. Nixes FirstBank Appeal In Merger Fraud Suit
• Pfizer Unit Recalls Pain Drug Embeda
• Apotex Doesn't Infringe Provigil Patent, Judge Says
• Braintree Hits Amrutham With Laxative Patent Suit
• Teva Exits Astellas Patent Suit Over Cancer Drug
• Tekmira Claims Alnylam Stole Gene Therapy Secrets
• Baxter Pockets Partial Costs In ERISA Win
• Triad Halts Production Of Pads Tied To Child's Death
• Premier Wins Bid To Arbitrate Rival's Antitrust Suit
• Endo Sues Mylan Over Generic Lidoderm Patch
• Cephalon Tries To Nix Approval For Generic Fentora
• Alnylam, German Group Settle RNA Patent App Case
• Gilead, Roche Sue To Block Generic Tamiflu
• IP Official Recommends Stronger Enforcement Plan
• Reviving Time-Barred Actions Via Legislation
• Merger Negotiations Can Stay Private — Usually
• Rite Aid Managers Take OT Actions To 3rd Circ.
• AstraZeneca Says SC Seroquel Suit Is Money Grab
• Ulmer & Berne Adds Ex-Dinsmore & Shohl Litigator
• Stragent Slaps Infineon, Others With Tech Patent Suit
• Fed. Circ. Won't Revisit Abraxis Loss In Naropin Suit
• Ex-Exactech Director Avoids Prison In Kickback Case
• Ropes & Gray Lures Life Sciences Atty From Goodwin
• White House Moves To Combine Trade Agencies
• Watson Wins Invalidity Ruling On 2 Fentora Patents
• Aventis, Sandoz Drop Swords In Taxotere Patent Suit
• 2nd Circ. Kills B&L Indemnity Bid, Not Defense Claim
• Minn. Pharmacy Class Suit Wrongly Remanded: 8th Circ.
• FDA Chief Backs $4.3B Budget In House Hearing
• MoFo Snags M&A Pro From Cooley For Calif. Office
• A Shot In The Arm For Section 2 Enforcement
• Patients Sue Genzyme Over Fabrazyme Rationing
• J&J Unit Agrees To Stop Making Drugs At Pa. Plant
• Ex-KV CEO Gets 1 Month, $1M Fine For False Drug Marks
• Judge Delays Approval Of SEC Deal With Body Armor Co.
• EU Embryo Patent Ban Covers Stem Cells: Court Adviser
• Becton Asks Fed. Circ. To Chuck $5M Syringe IP Loss
• Merchant & Gould Adds Hatch-Waxman Guru To IP Team
• AstraZeneca Seeks To Block Ex-Consultant's Testimony
• AstraZeneca To Pay $69M To States Over Seroquel
• 2010 In Review: Canadian Competition And Marketing
• Judge Certifies Mass. Class In CVS False Ad Suit
• Generics Maker Sues 3M In Skin Cream Row
• Gaims Weil Can't Ditch Wiretap Claims: Calif. Court
• American Capital Can't Nix Insurers' Heparin Suit
• Corporate Vet Joins Dentsply As General Counsel
• Allergan, Rivals Debate Competition Claims' Validity
• Abbott Can't Escape Suit Over Insects In Baby Formula
• Child Deaths Not Linked To Vaccines: Japan Drug Panel
• Noteholders To Buy Metamorphix Assets For $6M
• BSC, St. Jude Reach Deal Over Sales Exec Noncompete
• Ex-Best Medical Workers Slip Cancer Therapy IP Suit
• Mass. Targets Fund Over Use Of Expert Network Info
• Fla. Judge Backs Contract For Prescription Program
• Latham Reps Catalyst In $525M Walgreen Unit Buy
• Arrow, J&J Liability Claims Preempted: 11th Circ.
• FDA Warns Of Risks To Babies From HIV Drug Kaletra
• Fed. Circ. Kills Mylan's Prilosec Antitrust Claims
• FTC Blesses GTCR's $675M Purchase Of Sterigenics
• GSK Sales Reps Seek 9th Circ. Rehearing On OT Status
• Fueling The BPCI Debate
• Drugmakers Beat Price-Fixing Claims In Ca. Court
• Caremark Can't Ditch Contract Claims In Coventry Suit
• Gibson Dunn Reps Accuray In $277M Radiotherapy Deal
• Generics Co. Asks Fed. Circ. To Revive Fortican Claims
• Bovie, Medtronic Settle IP Suit Over Surgical Device
• Watson, Orchid Defenses Live In Generic Azilect Row
• AstraZeneca, Mylan Spar Over Prilosec Suit Dismissal
• High Court Denies Cert In Biopsy Tool Patent Suit
• MoFo Reps Terumo In $2.6B Gambro Unit Deal
• Japan Halts Pfizer, Sanofi Pediatric Vaccines
• Kirkland & Ellis Nabs IP Veteran From Jones Day
• Maximizing Your Chance At Federal Dollars
• Top Court Refuses To Hear Pay-For-Delay Challenge
• Gov'ts Win Cert. In McKesson Price-Rigging Suit
• Mylan, Others Hit With Class Action Over Painkillers
• Blackstone Sues Taro For $6M In Unpaid Merger Fees
• Drug Supply Co. Fraud Suit Referred To Mediation
• Cephalon Bid For Apotex Docs Denied In Provigil Suit
• Occlutech Implants Don't Violate IP: Swedish Court
• Sterilizer Co. To Pay $20M In Medical Device Action
• Ex-Cyberonics CEO Defies Options Reports In 2nd Circ.
• Howrey Attys Flee To Dewey & LeBoeuf, Perkins Coie
• Merck Must Face Unjust Firing Suit, 1st Circ. Rules
• UnitedHealth Hit With ERISA Class Action
• Spain Hits Hair Care Cos. With $71M Cartel Fine
• FDA To Up Topamax Warning Over Birth Defect Data
• Cigna Worker Launches $100M Sex Bias Action
• Immunizing Vaccine Manufacturers From State Claims
• Allergan Tries To Nix Breast Implant Marking Suit
• Merck Settles Trade Secrets Row Over Software
• J&J's Ethicon Unit Reveals Surgical Suture Recall
• Fed. Circ. Invalidates Crafco Patent For Obviousness
• McKesson Fights $212M Ariz. Fine Over Drug Prices
• Fulbright Picks Up 2 Litigators For LA Office
• Neuralstem Calls StemCells Patents 'Unenforceable'
• Insurers Freed From Tissue Donation Coverage Suit
• Shareholder Seeks To Halt $1.2B Clinical Data Sale
• FDA Cracks Down On Unapproved Cold, Cough Drugs
• Merck, Teva End Cancidas Patent Fight
• Astellas Sued Over Efforts To Block Generic Prograf
• Pay-For-Delay Deals Stay Under Wraps In Cephalon Suit
• FTC Gives Green Light To $1.25B CVS-Universal Deal
• KemPharm Hits Shire With Antitrust Counterclaims
• Allergan's Acadia Securities Sales Spark SEC Subpoenas
• Simpson Reps Daiichi Sankyo In $805M Plexxikon Buy
• Howrey Partners Defect To MoFo, Kirkland, Others
• GenMark Drops Suit Over Caliper Microfluidics Patents
• ClearCorrect Faces IP, Competition Suits Over Braces
• Beware Of GSA's Price Reductions Clause